Table 3. Studies reporting quantitative data for adverse events (AEs) after ivermectin-albendazole co-administration (n = 24).
| Reference no. | Study | Study type | Country | Disease (parasite) | IVM+ALB | IVM | ALB | |||
|---|---|---|---|---|---|---|---|---|---|---|
| No. treated | No. AEs | No. treated | No. AEs | No. treated | No. AEs | |||||
| [43] | Addis et al., 1997 | Trial (RCT) | Haiti | wb | 44 | NR | 43 | NR | 27 | NR |
| [44] | Amsden et al., 2007 | Trial (open) | USA | healthy | 18 | 1 | - | - | - | - |
| [45] | Anto et al., 2011 | Trial (matched) | Ghana | sh, sm, (wb, onc) | 15552 | 130 | - | - | - | - |
| [37] | Asio et al., 2009a | Trial (matched) | Uganda | mp | 15 | 0 | 15 | 0 | 13 | 0 |
| [38] | Asio et al., 2009b | Trial (RCT) | Uganda | mp | 86 | 0 | 96 | 0 | - | - |
| [40] | Awadzi et al., 2003$ | Trial (RCT) | Ghana | onc | 14 | 14 | 14 | 11 | 14 | 13 |
| [46] | Coulibaly et al., 2015 | prospective cross-sectional | Mali | wb | 2135 | 13 | - | - | - | - |
| [47] | Dembele et al., 2010† | Trial (RCT) | Mali | wb, mp | 42 | 9 | - | - | - | - |
| [41] | Dunyo et al., 2000 | Trial (RCT) | Ghana | wb | 332 | 47 | 295 | 36 | 336 | 31 |
| [48] | Hodges et al., 2010 | MDA post-treatment reporting | Sierra Leone | wb | 1104407 | 146 | - | - | - | - |
| [49] | Ismail et al., 1998 | Trial (blinded) | Sri Lanka | wb | 13 | NR | - | - | 12 | NR |
| [50] | Ismail et al., 2001# | Trial (blinded) | Sri Lanka | wb | 31 | NR | - | - | - | - |
| [51] | Keiser et al., 2003 | Trial (blinded) | Mali | wb, mp | 40 | 11 | - | - | - | - |
| [20] | Knopp et al., 2010* | Trial (RCT) | Tanzania (Unguja island) | tri | 144 | 64 | - | - | 136 | 60 |
| [42] | Makunde et al., 2003 | Trial (RCT) | Tanzania (mainland) | wb, onc | 20 | 11 | - | - | 13 | 5 |
| [52] | Na-Bangchang et al., 2006 | Trial (open) | Thailand | healthy | 23 | 0 | - | - | - | - |
| [30] | Ndyomugyenyi et al., 2008 | Trial (RCT) | Uganda | sth | 199 | 8 | 198 | 24 | 194 | 16 |
| [39] | Shenoy et al., 1999 | Trial (open) | India | bm | 16 | 12 | - | - | 3 | 2 |
| [53] | Shenoy et al., 2000 | Trial (open) | India | bm | 12 | 6 | - | - | - | - |
| [54] | Simonsen et al., 2004 | Trial (RCT) | Tanzania (mainland) | wb | 586 | NR | - | - | 635 | NR |
| [24] | Speich et al., 2015 | Trial (RCT) | Tanzania (Pemba island) |
tri | 108 | 22 | - | - | - | - |
| [55] | Tafatatha et al., 2015 | Trial (RCT) | Malawi | wb | 70 | 22 | - | - | - | - |
| [56] | Turner et al., 2006 | Trial (RCT) | Ghana | wb, wbb | 28 | 20 | - | - | - | - |
| [57] | WHO, 2003 | MDA post-treatment reporting | Burkina Faso, Nigeria, Tanzania (Mafia & Zanzibar islands) | lf | 9831 | 2358 | - | - | - | - |
$No. of AEs based on positive vs. zero Mazzotti reaction scores.
†Two different schemes of IVM/ALB combination: 150 μg/kg+400 mg (n = 22) and 400 μg/kg+800 mg (n = 20)
#Two different schemes of IVM/ALB combination: 200 μg/kg+400 mg (n = 16) and 400 μg/kg+600 mg (n = 15).
*No. of AEs instead of no. of participants with AEs.
Disease (parasite) abbreviations: bm = Brugia malayi, lf = lymphatic filariasis (species not specified), mp = Mansonella perstans, onc = Onchocerca volvulus, sh = Schistosoma haematobium, sm = Schistosoma mansoni, sth = soil-transmitted helminths, tri = Trichuris, wb = Wuchereria bancrofti, wbb = Wolbachia bacteria
RCT = randomized controlled trial, NR = not reported: no overall number of patients with AEs or AEs itself provided, AE frequencies only given for specific symptoms.
Studies in bold were subjected to meta-analysis.